Beta test rollout. This site is in community QA — please send feature requests, bug reports and data corrections on the Feedback page or on GitHub.

Home
    Disclaimer
    Psilocin molecular structure

    Psilocin Stats & Data

    4-ho-dmt 4-oh-dmt Psilocine Psilotsin
    PubChem
    MW204.27
    FormulaC12H16N2O
    LogP2.1
    IUPAC3-[2-(dimethylamino)ethyl]-1H-indol-4-ol
    InChIKeySPCIYGNTAMCTRO-UHFFFAOYSA-N
    Chemical Class Substituted tryptamine
    Psychoactive Class Psychedelic

    Pharmacology

    DrugBank

    Metabolism

    Psilocin has known human metabolites that include (2S,3S,4S,5R)-6-[3-[2-(dimethylamino)ethyl-1H-indol-4-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid.

    Receptor Profile

    Receptor Actions

    Agonists
    5-HT2A receptor partial agonist
    5-HT2C receptor agonist
    5-HT1A receptor agonist
    Other
    Activates phospholipase A2 instead of phospholipase C

    Measured Affinities

    Guide to PHARMACOLOGY

    Measured binding and functional data for psilocin, curated by the IUPHAR/BPS Guide to PHARMACOLOGY. Each row cites the paper it came from. Lower concentrations mean tighter binding — a value in the sub-nanomolar range indicates a very potent interaction.

    Target Action Measure Value Concentration Species Source
    5-HT2A receptor HTR2A Agonist pEC50 7.62 23.99 nM Human PMID 16061378

    Reading this. pKi, pEC50 and pIC50 are negative log molar values, so a higher number means a tighter interaction; the concentration column converts them for you. Values from non-human species are laboratory measurements and do not translate directly to human effect. Receptor affinity is not a dose — it describes what a molecule binds, not how much of it is safe to take.

    Receptor data from the IUPHAR/BPS Guide to PHARMACOLOGY (v2026.2), licensed CC BY-SA 4.0. Matched to this substance by InChIKey.

    Subjective Effects

    Physical
    • Spontaneous tactile sensations: The "body high" of psilocin can be described as a pleasurable, warm, soft and all-encompassing tingling sensation. This maintains a consistent presence that steadily rises with the onset and hits its limit once the peak has been reached.
    • Sedation: In terms of its effects on the physical energy levels of the tripper, psilocin is considered by most to be relaxing, stoning and mildly sedating. This sense of sedation is often accompanied by compulsive yawning.
    • Runny nose
    • Excessive yawning
    • Watery eyes
    • Nausea
    • Changes in gravity
    • Salivation
    • Pupil dilation
    Cognitive
    • Current mind state enhancement
    • Thought connectivity
    • Novelty enhancement
    • Time distortion
    • Analysis enhancement: This effect is consistent in its manifestation and outrospection dominant.
    • Déjà vu
    • Personal bias suppression
    • Feelings of predeterminism
    • Immersion enhancement
    • Conceptual thinking
    • Direct communication with the subconscious
    • Memory suppression
    • Feelings of interdependent opposites
    • Delusions
    • Unity and interconnectedness
    • Feelings of self-design
    • Exposure to inner mechanics of consciousness
    • Spirituality enhancement
    • Enhancement and suppression cycles: This can be described as constant waves of extremely stimulated and profound thinking which are spontaneously surpassed in a cyclic fashion by waves of general thought suppression and mental intoxication. These two states seem to switch between each other in a consistent loop once every 20 - 60 minutes.
    Sensory
    Auditory
    • Enhancements
    • Distortions
    • Hallucinations
    Visual · Distortions

    As for visual distortions and alterations, the effects experienced are detailed below:

    • Drifting: (Melting, Flowing, Breathing and morphing) - In comparison to other psychedelics, this effect can be described as highly detailed, realistic, slow and smooth in motion and static in appearance.
    • Tracers
    • After images
    • Symmetrical texture repetition
    • Colour shifting
    • Scenery slicing
    Visual · Enhancements

    Psilocin presents a full and complete array of possible visual enhancements which generally includes:

    • Visual acuity enhancement
    • Colour enhancement
    • Pattern recognition enhancement
    Visual · Hallucinatory States

    Psilocin and its various other forms produce a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of many other commonly used psychedelics. These effects generally include:

    • Transformations
    • Internal hallucinations: (Autonomous entities, Settings, sceneries, and landscapes, Alterations in perspective and Scenarios and plots) - This effect is very consistent in dark environments at appropriately high dosages. They can be comprehensively described through their variations as lucid in believability, interactive in style, new experiences in content, autonomous in controllability, geometry-based in style and almost exclusively of a religious, spiritual, mystical, science fiction or transcendental nature in their overall theme.

    Forked from Subjective Effect Documentation work by Josie Kins, April 2015. Via dose.wiki (CC0).

    Psilocin is non-addictive, is not known to cause brain damage, and has an extremely low toxicity relative to dose. Similar to other psychedelic drugs, there are relatively few physical side effects associated with acute psilocin exposure. Various studies have shown that in reasonable doses in a careful context, it presents little to no negative cognitive, psychiatric or toxic physical consequences.

    Carcinogenicity

    No indication of carcinogenicity to humans (not listed by IARC).

    Effect Profile

    Curated + 6 Reports
    Psychedelic 5.1

    Moderate visuals with mild headspace and body load, low auditory effects

    Visual Intensity×3
    6
    Headspace Depth×3
    5
    Auditory Effects×1
    3
    Body Load / Somatic Effects×1
    5
    Empathogen 4.6

    Strong sensory enhancement with moderate euphoria, low empathy and stimulation

    Empathy / Social Openness×3
    3
    Euphoria / Mood Elevation×2
    6
    Stimulation×1
    3
    Sensory Enhancement×1
    8

    Duration Timeline

    Bluelight
    Onset Comeup Peak Offset After Effects
    Oral
    19-45 minutes
    1.5-3 hours
    2-3 hours
    1.5-2 hours
    4-24 hours
    Insufflated
    4-10 minutes
    2.0-4.0 hours
    3.0-12.0 hours

    Tolerance & Pharmacokinetics

    drugs.wiki

    Tolerance Decay

    Full tolerance 1h Half tolerance 10d Baseline ~14d

    Cross-Tolerances

    LSD
    Psilocybin
    Mescaline
    DMT
    5-MeO-DMT
    2C-B
    2C-E
    2C-I

    Experience Report Analysis

    Erowid
    12 Reports
    6 Single-substance
    2004–2022 Date Range
    6 With Age Data
    11 Effects Detected

    Demographics

    Gender Distribution

    Too few reports for a chart: gender is known from 12 reports, and a split is drawn only from 20 reports or more. Counts are shown instead. Why 20?

    • Male 12 of 12

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 6 experience reports (6 single-substance Erowid)

    6 Reports
    11 Effects Detected
    8 Positive
    2 Adverse
    1 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

    Too few reports for bars: these effects come from 6 single-substance Erowid reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

    Positive Effects 8

    Visual Distortions 6 of 6 70%
    Empathy 5 of 6 70%
    Music Enhancement 5 of 6 70%
    Color Enhancement 5 of 6 70%
    Body High 3 of 6 70%
    Euphoria 3 of 6 70%
    Stimulation 3 of 6 70%
    Closed-Eye Visuals 3 of 6 70%

    Adverse Effects 2

    Anxiety 4 of 6 70%
    Nausea 3 of 6 70%
    Show 1 neutral or unclassified mention
    Ego Dissolution 4 of 6

    Also reported in combinations. In the 6 Psilocin reports where another drug was taken too, 1 mentions hospital, emergency services or an overdose, 0 a seizure and 1 psychosis (too few reports for percentages). In the 6 single-substance reports: 0, 0 and 1. These are not in the figures above: they cannot be put down to Psilocin alone, and a mention is not always something that happened to the writer.

    Real-World Dose Distribution

    Erowid

    From 13 of 20 recorded dose entries: those that state a weight (mg, g or µg), in routes with at least five of them. Values above Q3 + 3×IQR, far above what people typically take, are left out; they can include real heavy doses and overdoses, not only mistakes.

    Oral (n=13)

    Median: 15.0mg 25th: 11.0mg 75th: 20.0mg 90th: 25.8mg

    Form / Preparation

    Most common forms and preparations, as a share of the 8 reports that give one

    Too few reports for bars: these forms come from 8 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

    • Liquid 3 of 8
    • Powder / Crystals 3 of 8
    • Capsule 2 of 8

    Legal Status

    Controlled internationally under the UN Convention on Psychotropic Substances 1971.
    Country Status Notes
    Australia Psilocin is considered a Schedule 9 prohibited substance in Australia under the Poisons Standard (October 2015). A Schedule 9 substance is a substance which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.
    Russia Psilocin and psilocybin are banned in Russia, due to their status as narcotic drugs, with a criminal penalty for possession of more than 50 mg.
    United States Psilocin is a Schedule I controlled substance in the United States since 1971.
    ← Back to Psilocin